Inês Martins, PhD,  managing science editor—

When amyotrophic lateral sclerosis (ALS) symptoms emerge during adolescence, mutations in the FUS gene are likely to blame, findings from a case report suggest. Mutations in this gene also are the cause of some adult-onset ALS cases. However, FUS-associated ALS is more aggressive in children in whom these…

Levels of plasma creatinine — a metabolic product of healthy muscle — are significantly associated with the functional status of amyotrophic lateral sclerosis (ALS) patients, and can help predict their survival, results from a new study show. The findings suggest that plasma creatinine may be an important biomarker…

Fasudil, approved in Japan for treating stroke patients, also is well-tolerated and prevents disease worsening in people with amyotrophic lateral sclerosis (ALS), according to a report of three patients who received the medicine under compassionate use. However, the effects were transient, and all three patients experienced either a decline…

Mutations in the TBK1 gene — often associated with amyotrophic lateral sclerosis (ALS) — seem to have a dual role in progression of the disease, causing it to emerge earlier in animals models of ALS, but then slowing in later stages. This paradoxical role, according to a results…

The onset and early progression of motor and cognitive symptoms, specific by disease type to each amyotrophic lateral sclerosis (ALS) patient, are determined by age and sex, and to some extent by mutations in ALS genes, a large data study has found. The study, “ALS phenotype is influenced…

AB Science plans to launch a Phase 3 clinical trial testing the safety and effectiveness of its tyrosine kinase inhibitor masitinib as an add-on treatment for people with amyotrophic lateral sclerosis (ALS). Its announcement follows U.S. Food and Drug Administration (FDA) approval of the company’s investigational new…

A single brain area previously thought to control only the movement of the hands and arms also may control movement across all four limbs, a study found. This discovery opens new avenues for the use of brain-computer interfaces in people who have lost control of their arms and legs,…

People with amyotrophic lateral sclerosis (ALS) are less likely to have used anti-diabetic medications in the five years preceding their diagnosis than matched individuals of the same population, a study found, supporting an inverse association between diabetes treatments and the risk of ALS. The research also points to…

Radicava (edaravone), an approved treatment for amyotrophic lateral sclerosis (ALS), can be taken for up to one year without losing its effectiveness, and benefits patients who delay its start — say, after six months of placebo in a clinical trial, a post hoc analysis of that Phase 3…

Amyotrophic lateral sclerosis (ALS) patients receiving the lowest dose of Kadimastem’s cell therapy candidate, AstroRx, experienced a significant reduction in disease progression in the three or four months after treatment, updated findings from the company’s Phase 1/2 clinical trial show. In subsequent…